Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer

Everolimus is an inhibitor of mammalian target of rapamycin with anti-tumour activity. While everolimus is known to cause drug-induced pneumonitis, it is rarely associated with Pneumocystis jirovecii pneumonia (PJP). We report a patient on everolimus therapy for metastatic breast cancer that develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuik, Kelvin Teck-Hong, Trubiano, Jason, Worth, Leon J., Harun, Nur-shirin, Steinfort, Daniel, Johnson, Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216328/
https://www.ncbi.nlm.nih.gov/pubmed/25379397
http://dx.doi.org/10.1016/j.mmcr.2014.08.007
Descripción
Sumario:Everolimus is an inhibitor of mammalian target of rapamycin with anti-tumour activity. While everolimus is known to cause drug-induced pneumonitis, it is rarely associated with Pneumocystis jirovecii pneumonia (PJP). We report a patient on everolimus therapy for metastatic breast cancer that developed PJP. Diagnosis was based on clinical features and a quantitative polymerase chain reaction for P. jirovecii DNA. Clinicians should consider PJP as a potential cause of pulmonary infiltrates in patients treated with everolimus.

Ejemplares similares